Federico Innocenti, MD, PhD
The University of North Carolina at Chapel Hill
Genetics of VEGFR-2 in Bronchioalveolar Carcinoma
Dr. Innocenti is investigating differences in the genes that determine how new blood vessels are formed (angiogenesis). He will be analyzing the vascular endothelial growth factors receptor 2 (VEGFR2), to see how the activity and levels of this protein vary in different BACs, and determine if there is a genetic basis for the differences observed in patients with BAC.
Dr. Innocenti has found altered expression of these genes in BAC tumor samples compared to normal tissue. He has also identified a heritable gene variation that may reduce expression of VEGRF-2 in adenocarcinoma with BAC features. Further studies are warranted to expand the sample size to replicate and validate these findings.